Chordia Therapeutics (TSE:190A) PS Ratio: (As of Aug. 04, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:190A Chordia Therapeutics Inc TSE:190A
12 GF Score
Price 円78.00
! 2 Warning Signs
View Full Analysis

What is Chordia Therapeutics PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Chordia Therapeutics's share price is 円78.00. Chordia Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Feb. 2026 was 円0.00. Hence, Chordia Therapeutics's PS Ratio for today is .

The historical rank and industry rank for Chordia Therapeutics's PS Ratio or its related term are showing as below:

During the past 5 years, Chordia Therapeutics's highest PS Ratio was 18.76. The lowest was 1.51. And the median was 4.43.

TSE:190A's PS Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 8.91
* Ranked among companies with meaningful PS Ratio only.

Chordia Therapeutics's Revenue per Sharefor the six months ended in Feb. 2026 was 円0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Feb. 2026 was 円0.00.

Back to Basics: PS Ratio


Chordia Therapeutics  (TSE:190A) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Chordia Therapeutics PS Ratio Related Terms


Chordia Therapeutics PS Ratio Historical Data

* Premium members only.

The historical data trend for Chordia Therapeutics's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chordia Therapeutics PS Ratio Chart

Chordia Therapeutics Annual Data
Trend Aug21 Aug22 Aug23 Aug24 Aug25
PS Ratio
0.00 0.00 0.00 0.00 0.00

Chordia Therapeutics Semi-Annual Data
Aug21 Aug22 Aug23 Feb24 Aug24 Feb25 Aug25 Feb26
PS Ratio Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

TSE:190A vs VRTX, REGN, RVMD: PS Ratio Comparison

For the Biotechnology subindustry, Chordia Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chordia Therapeutics PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chordia Therapeutics's PS Ratio distribution charts can be found below:

* The bar in red indicates where Chordia Therapeutics's PS Ratio falls into.


TSE:190A
12GF Score
Chordia Therapeutics Inc TSE:190A
PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chordia Therapeutics PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Chordia Therapeutics's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=78.00/0
=

Chordia Therapeutics's Share Price of today is 円78.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Chordia Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Feb. 2026 was 円0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Chordia Therapeutics Business Description

Address 2-26-1 Muraoka-Higashi, Kanagawa, Fujisawa, JPN, 251-0012
Chordia Therapeutics Inc is a bio-venture company specializing in cancer research and development. Its mission is to deliver first-in-class cancer drugs to patients. It is a clinical-stage biotech company engaged in researching and developing novel therapies for cancers with high unmet medical needs.
12GF Score

Get the complete analysis for TSE:190A

PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円78.00
Price